Lupin Limited has entered into a strategic licensing and supply agreement with Galenicum Health, S.L.U. for injectable Semaglutide, marking a significant expansion of the pharmaceutical company's diabetes care portfolio across international markets.

Partnership Structure and Scope

The agreement, executed through Lupin's subsidiary Lupin Atlantis Holdings SA (LAHSA), covers finished formulations of injectable Semaglutide, a GLP-1 receptor agonist, across 23 countries globally. The partnership encompasses key markets including Canada, Europe, Southeast Asia and Latin America.

Strategic Market Positioning

Fabrice Egros, President, Corporate Development at Lupin, emphasized the partnership's significance in strengthening the company's Semaglutide portfolio. The collaboration positions Lupin to capitalize on worldwide growth opportunities in the expanding GLP-1 market, leveraging the company's extensive commercial presence across the targeted regions.

Semaglutide represents a critical therapy as diabetes continues to escalate globally and obesity emerges as a major health priority. The partnership enables Lupin to scale access to this important medication while reinforcing its commitment to delivering high-quality, cost-effective medicines.

Product Overview and Applications

Semaglutide is a generic form of glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar and appetite. The medication serves dual therapeutic purposes:

• Diabetes Management: Prescribed for adults with Type 2 Diabetes alongside diet and exercise
• Weight Management: Used for long-term weight management in adults with obesity or overweight conditions

Galenicum's Strategic Focus

Joaquim Domingo, co-founder of Galenicum, highlighted the partnership as a cornerstone of the company's strategy to scale high-impact volumes of Semaglutide globally. Galenicum has invested heavily in its GLP-1 development pipeline to meet the surging demand for these therapies, positioning itself as a leader in the B2B GLP-1 space.

The Barcelona-based company operates across more than 70 countries worldwide, maintaining a diversified portfolio across key therapeutic areas including cardiovascular, central nervous system, pain management, and anti-infectives, with particular strength in diabetes care.

Company Profiles

Lupin Limited operates as a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. The company maintains 15 state-of-the-art manufacturing sites and 7 research centers globally, supported by over 24,000 professionals. Lupin specializes in pharmaceutical products including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

Galenicum Health, headquartered in Esplugues de Llobregat, Barcelona, Spain, specializes in the development, manufacturing, and commercialization of generic medicines and value-added generics. The company focuses on affordability and quality, serving patients and healthcare systems across Europe, Latin America, Asia, and Africa through its state-of-the-art manufacturing facility and dedicated R&D centers.

Lupin Limited has received an Environmental, Social and Governance (ESG) rating of 67 from ESG Risk Assessments & Insights Limited, positioning the pharmaceutical company in the Strong category. The company disclosed this development to stock exchanges on January 19, 2026, in compliance with regulatory requirements.

ESG Rating Details

The assessment was conducted independently by ESG Risk Assessments & Insights Limited without any direct engagement from Lupin. The rating agency prepared its evaluation based entirely on publicly available company data and information in the public domain.

Regulatory Compliance

Lupin made the disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notification was sent to both the National Stock Exchange of India Limited and BSE Limited as part of the company's ongoing compliance obligations.

The disclosure was signed by Amit Kumar Gupta, Company Secretary & Compliance Officer, emphasizing the company's commitment to transparency in ESG-related developments. The independent nature of the assessment highlights that Lupin did not commission or influence the rating process.

Market Significance

The Strong category ESG rating reflects positively on Lupin's environmental, social, and governance practices. ESG ratings have become increasingly important for investors and stakeholders in evaluating companies' sustainability performance and long-term value creation potential. The rating of 67 demonstrates Lupin's performance across various ESG parameters as assessed through publicly available information.